Sensex
74,775.74 profit arw -1,092.06 (-1.44%)
Nifty
23,547.75 profit arw -359.40 (-1.50%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 06-Mar-2026
Corporate News
06-Mar-2026     09:43

Alembic Pharmaceuticals announces first prescription-based sale of Pivya' (pivmecillinam) tablets

Alembic Pharmaceuticals today announced the first prescription-based sale of Pivya' (pivmecillinam) tablets, an oral prescription antibiotic, following its recent commercial launch in the United States of America (US). Pivya' is Alembic's first branded pharmaceutical product in the US and is being marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of Alembic.

Pivya' represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

74,775.74 -1,092.06 (-1.44%)

Nifty

23,547.75 -359.40 (-1.50%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,182.40 176.23(0.70%)